Vertex Pharmaceuticals Inc
VRTX· Nasdaq
Released Aug 3, 2026, after the close
10-Q filed Aug 4, 2026, 35 days after period end · 0000875320-26-000259
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $3.33B | $2.96B | $2.65B | $2.49B |
| Net Income | $1.10B | $1.03B | -$3.59B | $915.70M |
| EPS Diluted |
Vertex Pharmaceuticals Inc · CIK 875320 · Engraved from SEC EDGAR
| $4.31 |
| $3.99 |
| -$13.92 |
| $3.52 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.